GAMMAGARD

This brand name is authorized in United States. It is also authorized in Austria, Canada, Finland, France, Ireland, Japan, Netherlands, Poland, Singapore, Spain, UK.

Active ingredients

The drug GAMMAGARD contains one active pharmaceutical ingredient (API):

1	Immunoglobulins, normal human, IV UNII 66Y330CJHS - HUMAN IMMUNOGLOBULIN G
	Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.
	Read more about Immunoglobulins, normal human, IV

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BA02	Immunoglobulins, normal human, for intravascular adm.	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BA Immunoglobulins, normal human
Discover more medicines within J06BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02231470, 02231471, 02279444
ES	Centro de información online de medicamentos de la AEMPS	60717, 60718
FI	Lääkealan turvallisuus- ja kehittämiskeskus	559161, 559187
FR	Base de données publique des médicaments	68399068
GB	Medicines & Healthcare Products Regulatory Agency	47641, 47654
JP	医薬品医療機器総合機構	6343420X2029
NL	Z-Index G-Standaard	13897152, 13897160
NL	Z-Index G-Standaard, PRK	41084, 41092
PL	Rejestru Produktów Leczniczych	100193036
SG	Health Sciences Authority	08493P
US	FDA, National Drug Code	0944-2700